N,N-dimethyl-8,8-dipropyl-2-azaspiro [4,5] decane-2-propanamine dihydrochloride | 123018-34-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: N,N-dimethyl-8,8-dipropyl-2-azaspiro [4,5] decane-2-propanamine dihydrochloride
• 英文别名: SKandF 105685；N,N-dimethyl-8,8-dipropyl-2-azaspiro[4,5]-decane-2-propanamine；2-Azaspiro(4.5)decane-2-propanamine, N,N-dimethyl-8,8-dipropyl-；3-(8,8-dipropyl-2-azaspiro[4.5]decan-2-yl)-N,N-dimethylpropan-1-amine
• CAS: 123018-34-8
• 化学式: C₂₀H₄₀N₂
• 分子量: 308.551
• InChiKey: AQQJKZQCFJQLOU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N-dimethyl-8,8-dipropyl-2-azaspiro [4,5] decane-2-propanamine dihydrochloride 、 、 顺丁烯二酸 在 乙酸乙酯 作用下， 以 乙酸乙酯 为溶剂， 反应 123.0h， 以to yield the title compound (650 g)的产率得到N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamine dimaleate
  参考文献：
  名称：

  N,N-dimethyl-8,8-dipropyl-2-azaspiro\x9b4.5!decane-2-propanamine dimaleate

  摘要：

  一种改进的免疫调节剂，即N,N-二甲基-8,8-二丙基-2-氮杂螺[4.5]癸烷-2-丙胺的二马来酸盐。

  公开号：

  US05939450A1
• 作为产物：
  描述：

  8,8-二丙基-2-噁-螺[4.5]-1,3-癸二酮 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 3.0h， 生成 N,N-dimethyl-8,8-dipropyl-2-azaspiro [4,5] decane-2-propanamine dihydrochloride
  参考文献：
  名称：

  Antiarthritic and supressor cell inducing activity of azaspiranes: structure-function relationships of a novel class of immunomodulatory agents

  摘要：

  Spirogermanium (1; 8,8-diethyl-N,N-dimethyl-2-aza-8- germaspiro[4.5]decane-2-propanamine dihydrochloride) is a potent cytotoxic agent in vitro which has demonstrated limited activity in experimental animal tumor models. Subsequently, it has been reported that spirogermanium has antiarthritic and suppressor cell-inducing activity. We have synthesized a series of substituted 8-hetero-2-azaspiro[4.5]decane and 9-hetero-3-azaspiro[5.5]undecane analogues of spirogermanium to identify the heteroatom requirements for in vivo antiarthritic and suppressor cell-inducing activity. This structure-activity relationship study has identified that appropriately substituted silicon and carbon analogues of spirogermanium retain both antiarthritic and immunosuppressive activity, with the 8,8-dipropyl (carbon) analogue being among the most active. Following the identification of N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamine++ + dihydrochloride (9) as a more active analogue than spirogermanium, a series of 8,8-dipropyl analogues with various amine substituents were synthesized. A number of these analogues had activity similar to that of 9. A correlation between activity in the adjuvant arthritic rat and the ability to induce suppressor cells (r = 0.894, p less than 0.001) suggests an association between the two pharmacologic effects. While the precise biochemical mechanism(s) for the pharmacological activity is unclear, these data suggest that compounds within this series, e.g., N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamine++ + dihydrochloride, may provide effective therapy in diseases of autoimmune origin and/or the prevention of rejection in tissue transplantation.

  DOI：

  10.1021/jm00173a010

文献信息

• Immunosuppressive compositions
  申请人：——

  公开号：US20010014676A1

  公开（公告）日：2001-08-16

  A pharmaceutical composition containing a non-specific (NS) suppressor cell inducing compound and a non NS suppressor cell cell inducing immunosuppressive compound and a pharmaceutically acceptable carrier or diluent, and method of inducing an immunosuppressive effect in a mammal, including a human, in need thereof which comprises administering an effective dose of a NS suppressor cell inducing compound and a non NS suppressor cell cell inducing immunosuppressive compound to such mammal.

  一种药物组合物，含有一种非特异性（NS）抑制细胞诱导化合物和一种非 NS 抑制细胞诱导免疫抑制化合物以及一种药学上可接受的载体或稀释剂，以及在有需要的哺乳动物（包括人类）体内诱导免疫抑制效应的方法，该方法包括向此类哺乳动物施用有效剂量的一种 NS 抑制细胞诱导化合物和一种非 NS 抑制细胞诱导免疫抑制化合物。
• IMMUNOSUPPRESSIVE COMPOSITIONS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0542860A1

  公开（公告）日：1993-05-26
• CYTOKINE INHIBITORS
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0572537A1

  公开（公告）日：1993-12-08
• EP0572537A4
  申请人：——

  公开号：EP0572537A4

  公开（公告）日：1993-10-14
• METHODS FOR TREATMENT OF HYPERLIPIDEMIA USING AZASPIRANES
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：EP0609358A1

  公开（公告）日：1994-08-10